Open label phase II study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) [rubitecan] administered as a `5 days on-2 days off' oral treatment in advanced/metastatic urothelial tract tumors.

Trial Profile

Open label phase II study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) [rubitecan] administered as a `5 days on-2 days off' oral treatment in advanced/metastatic urothelial tract tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2012

At a glance

  • Drugs Rubitecan (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top